Gilman Law LLP is Investigating OHR Pharmaceuticals, Inc. on Behalf of Purchasers of OHR Pharmaceuticals, Inc. Stock
About the OHR Pharmaceuticals, Inc.
The Investment Fraud Attorneys of Gilman Law LLP announce they are investigating potential federal securities law claims on behalf of investors in Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) common stock.
OHR Pharmaceuticals, Inc. Details of Investigation
On March 27, 2015, Ohr Pharmaceutical announced the results of a mid-stage study of its lead drug, OHR-102. The study was designed to determine whether the drug could be used in tandem with the existing treatment, injectable eye drug Lucentis, to reduce the number of Lucentis injections patients required. But Ohr announced that there was no “meaningful” reduction in the number of injections required when OHR-102 was used, and that its study had thus failed its primary endpoint.
Legal Help for OHR Pharmaceuticals, Inc. Investors
If you purchased or otherwise acquired shares of OHR Pharmaceuticals, Inc., you may have legal claims under federal securities laws. You may contact Gilman Law LLP to discuss your rights to recovery of your losses or to obtain additional information.
About Our Investment Fraud Attorneys
The Securities Fraud Attorneys at Gilman Law have over 35 years of experience in securities litigation. Our Investment Fraud Attorneys focus on cases involving securities litigation, securities fraud, mergers and acquisitions, breach of fiduciary duty and other shareholder disputes.
For a free evaluation of your case or to obtain additional information, please CALL TOLL FREE (888) 252-0048.